Evidence map›Paper›PMID 30024941›Full record

ArticlePloS one2018

Quantification of microRNA levels in plasma - Impact of preanalytical and analytical conditions.

Helle Glud Binderup, Jonna Skov Madsen, Niels Henrik Helweg Heegaard, Kim Houlind, Rikke Fredslund Andersen, Claus Lohman Brasen

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. IsomiR stoichiometry changes as disease biomarkers.Molecular therapy. Nucleic acids · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Helle Glud BinderupBiochemistry and Immunology, Lillebaelt Hospital, Kolding and Vejle, Denmark.ORCID 0000-0001-6698-9948
Jonna Skov MadsenBiochemistry and Immunology, Lillebaelt Hospital, Kolding and Vejle, Denmark.
Niels Henrik Helweg HeegaardDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark.
Kim HoulindDepartment of Regional Health Research, University of Southern Denmark, Kolding, Denmark.
Rikke Fredslund AndersenBiochemistry and Immunology, Lillebaelt Hospital, Kolding and Vejle, Denmark.
Claus Lohman BrasenBiochemistry and Immunology, Lillebaelt Hospital, Kolding and Vejle, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies have reported a potential role for circulating microRNAs as biomarkers in a wide variety of diseases. However, there is a critical reproducibility challenge some of which might be due to differences in preanalytical and/or analytical factors. Thus, in the current study we systematically investigated the impact of selected preanalytical and analytical variables on the measured microRNA levels in plasma. Similar levels of microRNA were found in platelet-poor plasma obtained by dual compared to prolonged single centrifugation. In contrast, poor correlation was observed between measurements in standard plasma compared to platelet-poor plasma. The correlation between quantitative real-time PCR and droplet digital PCR was found to be good, contrary to TaqMan Low Density Array and single TaqMan assays where no correlation could be demonstrated. Dependent on the specific microRNA measured and the normalization strategy used, the intra- and inter-assay variation of quantitative real-time PCR were found to be 4.2-6.8% and 10.5-31.4%, respectively. Using droplet digital PCR the intra-assay variation was 4.4-20.1%, and the inter-assay variation 5.7-26.7%. Plasma preparation and microRNA purification were found to account for 39-73% of the total intra-assay variation, dependent on the microRNA measured and the normalization strategy used. In conclusion, our study highlighted the importance of reporting comprehensive methodological information when publishing, allowing others to perform validation studies where preanalytical and analytical variables as causes for divergent results can be minimized. Furthermore, if microRNAs are to become routinely used diagnostic or prognostic biomarkers, the differences in plasma microRNA levels between health and diseased subjects must exceed the high preanalytical and analytical variability.

Indexed as

Molecular Diagnostic TechniquesPre-Analytical PhaseBiomarkersBlood PlateletsCentrifugationHumansMicroRNAsPlasmaPolymerase Chain ReactionBiomarkersMicroRNAs

Identifiers

PMID30024941
PMCPMC6053236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.